Get to Know Dr. Hossein Borghaei
He believes strongly in personalizing therapy, using a patient’s cancer type and genetics, along with their personal, social and family needs, in formulating an individualized treatment plan.
“I believe that we treat more than just a disease,” he said. “I consider the patient as a whole, an individual with a disease, and not just the disease. I believe in engaging patients and their families in their care to the extent that my patients allow it.”
Borghaei uses a multidisciplinary approach that includes the latest immunotherapies, along with potential surgical and radiological interventions for his patients. He is an active researcher with a deep interest in advancing treatment for mesothelioma and other malignancies.
He serves as chief in the Division of Thoracic Medical Oncology and co-director of the Immune Monitoring Facility at Fox Chase. He also is part of the Lung Cancer and Mesothelioma Translational Research Disease Group.
Specialties of Dr. Hossein Borghaei
- Lung cancer
- Endobronchial disease
- Pleural mesothelioma
- Molecular therapeutics
- Targeted therapy
Dr. Hossein Borghaei’s Experience and Education
- Fox Chase Cancer Center
- Fox Chase Cancer Center, Hematology-Oncology (Fellowship)
- Graduate Hospital, Philadelphia (Residency)
- Philadelphia College of Osteopathic Medicine (D.O.)
Awards and Certifications
- American Board of Internal Medicine
- National Board of Osteopathic Medical Examiners
- Medical Oncology
- American Society of Clinical Oncology
- American Association of Cancer Research
- National Comprehensive Cancer Network, Pleural Mesothelioma/Thymomas Committee
Publications of Dr. Hossein Borghaei
- Borghaei, H. et al. (2019, January 14). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. Journal of Thoracic Oncology.
- Borghaei, H. et al. (2015, October 22). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine.
- Moran, T. et al. (2014, November 7). Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. Experimental Hematology & Oncology.
- Borghaei, H. et al. (2009, September 1). Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology.
Thank you for your feedback. Would you like to speak with a Patient Advocate?